References
- World Health Organization [Internet]. Geneva: World Health Organization; [ cited 2017 Oct]. Available from: http://www.who.int.mediacentre/factsheets/fs164/en/
- Asselah T, Kowdley KV, Zadeikis N et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2017 Sep 22. [Epub ahead of print]. DOI:10.1016/j.cgh.2017.09.027
- Food and Drug Administration [Internet]. Silver Spring (MD): Food and Drug Administration; [ cited 2017 Aug 3]. Available from: http://www.accessdata.fda.gov/
- Poordad F, Pol S, Asatryan A, et al. Magellan-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology. 2017;152(Suppl 5):1057
- Zuezem S, Field J, Wang S, et al. Endurance-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. Presented at: American Association for the Study of Liver Disease Meeting; 2016 Nov 11–Nov 15; Boston, MA.
- Wyles D, Poordad F, Wang S et al. Glecaprevir/pibrentasvir for HCV genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase III clinical trial. Hepatology. 2017 Sep 19. [Epub ahead of print]. DOI:10.1002/hep.29541
- Foster GR, Gane E, Asatryan A et al. Endurance 3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis. J Hepatol. 2017;66(1):S33.
- Forns X, Lee S, Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1,2,4,5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068.
- Gane E, Lawitz E, Pugatch D et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15)1448–1455.
- Reau N, Kwo PY, Rhee S et al. MAGELLAN-2; safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection. J Hepatol. 2017;66(1):S90–S91.
- Food and Drug Administration [Internet]. Silver Spring (MD): Food and Drug Administration; [ cited 2016 Jun 28]. Available from: http://www.accessdata.fda.gov/
- Pol S, Pockros P, Pugatch D et al. Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 as a function of chronic kidney disease stage. Presented at European Association for the Study of the Liver; 2017 Apr 19–Apr 23; Amsterdam, The Netherlands.
- Krishnan P, Schnell G, Tripathi R et al. Pooled resistance analysis in HCV genotype 1–6 infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. J Hepatol. 2017;66(1):S500.